{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:04:02Z","timestamp":1788433442546,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jgar.2025.04.002","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T11:43:40Z","timestamp":1744285420000},"page":"51-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Role of low-frequency integrase strand transfer inhibitor resistance mutations on virological outcomes in antiretroviral therapy-na\u00efve individuals initiating second-generation integrase inhibitors"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3406-7014","authenticated-orcid":false,"given":"Daniele","family":"Armenia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta","family":"Marchegiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4932-5344","authenticated-orcid":false,"given":"Daniele","family":"Spalletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1713-8682","authenticated-orcid":false,"given":"Luca","family":"Carioti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Tavelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7717-2343","authenticated-orcid":false,"given":"Maria Concetta","family":"Bellocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Spagnuolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0240-7504","authenticated-orcid":false,"given":"Valentina","family":"Mazzotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Quiros-Roldan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Carrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4729-7548","authenticated-orcid":false,"given":"Sergio","family":"Lo Caputo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"D\u2019Arminio Monforte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ceccherini-Silberstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0375-9990","authenticated-orcid":false,"given":"Stefano","family":"Rusconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Mercedes","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2025.04.002_bib0001","unstructured":"DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guide- lines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV Developed by the DHHS Panel on Antiretroviral Guide- lines for Adults. https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/adult-adolescent-arv\/guidelines-adult-adolescent-arv.pdf 2024 [accessed 24.12.28]."},{"key":"10.1016\/j.jgar.2025.04.002_bib0002","unstructured":"European AIDS Clinical Society (EACS), European AIDS Clinical Society (EACS) Guidelines. Version 12.1 2024, https:\/\/www.eacsociety.org\/guidelines\/eacs-guidelines\/; November 2024 [accessed 24.12.28]."},{"key":"10.1016\/j.jgar.2025.04.002_bib0003","unstructured":"World Health Organization (WHO). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, https:\/\/iris.who.int\/bitstream\/handle\/10665\/342899\/9789240031593-eng.pdf?sequence=1; July 2021 [accessed 24.12.28]."},{"key":"10.1016\/j.jgar.2025.04.002_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12977-017-0360-7","article-title":"HIV drug resistance against strand transfer integrase inhibitors","volume":"14","author":"Anstett","year":"2017","journal-title":"Retrovirology"},{"key":"10.1016\/j.jgar.2025.04.002_bib0005","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3390\/v13020205","article-title":"Integrase strand transfer inhibitors are effective anti-HIV drugs","volume":"13","author":"Smith","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.jgar.2025.04.002_bib0006","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/1060028013513558","article-title":"Dolutegravir, a second-generation integrase inhibitor for the treatment of HIV-1 infection","volume":"48","author":"Rathbun","year":"2014","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jgar.2025.04.002_bib0007","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1128\/AAC.01474-16","article-title":"Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile","volume":"60","author":"Tsiang","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.04.002_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106027","article-title":"Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen","volume":"56","author":"Santoro","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2025.04.002_bib0009","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/jac\/dkz417","article-title":"Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance","volume":"75","author":"Tzou","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2025.04.002_bib0010","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/hiv.13556","article-title":"Rate of response to initial antiretroviral therapy according to level of pre-existing HIV-1 drug resistance detected by next-generation sequencing in the strategic timing of antiretroviral treatment (START) study","volume":"25","author":"Cozzi-Lepri","year":"2024","journal-title":"HIV Med"},{"key":"10.1016\/j.jgar.2025.04.002_bib0011","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1093\/jac\/dkaa309","article-title":"Surveillance of HIV-1 transmitted integrase strand transfer inhibitor resistance in the UK","volume":"75","author":"Mbisa","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2025.04.002_bib0012","doi-asserted-by":"crossref","DOI":"10.3390\/v12060617","article-title":"Next-generation sequencing for HIV drug resistance testing: laboratory, clinical, and implementation considerations","volume":"12","author":"\u00c1vila-R\u00edos","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.jgar.2025.04.002_bib0013","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/COH.0000000000000737","article-title":"Technologies for HIV-1 drug resistance testing: inventory and needs","volume":"17","author":"Metzner","year":"2022","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.jgar.2025.04.002_bib0014","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1093\/jac\/dky211","article-title":"Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor","volume":"73","author":"Raffaelli","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2025.04.002_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.718763","article-title":"Transmitted drug resistance in antiretroviral therapy-naive persons with acute\/early\/primary HIV infection: a systematic review and meta-analysis","volume":"12","author":"Guo","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jgar.2025.04.002_bib0016","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/cid\/ciab583","article-title":"Transmitted drug resistance among human immunodeficiency virus (HIV)-1 diagnoses in the United States, 2014-2018","volume":"74","author":"McClung","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.04.002_bib0017","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/cid\/ciac972","article-title":"Transmitted drug resistance to integrase-based first-line human immunodeficiency virus antiretroviral regimens in Mediterranean Europe","volume":"76","author":"de Salazar","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.04.002_bib0018","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1093\/jac\/dkae189","article-title":"HIV-1 transmitted drug resistance in newly diagnosed individuals in Italy over the period 2015-21","volume":"79","author":"Fabeni","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2025.04.002_bib0019","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/hiv.13038","article-title":"Transmitted HIV-1 drug resistance in a large international cohort using next-generation sequencing: results from the Strategic Timing of Antiretroviral Treatment (START) study","volume":"22","author":"Baxter","year":"2021","journal-title":"HIV Med"},{"key":"10.1016\/j.jgar.2025.04.002_bib0020","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/infdis\/jiz650","article-title":"Low-abundance drug-resistant HIV-1 variants in antiretroviral drug-naive individuals: a systematic review of detection methods, prevalence, and clinical impact","volume":"221","author":"Mbunkah","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jgar.2025.04.002_bib0021","doi-asserted-by":"crossref","first-page":"S847","DOI":"10.1093\/infdis\/jix430","article-title":"The role of HIV-1 drug-resistant minority variants in treatment failure","volume":"216","author":"Stella-Ascariz","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jgar.2025.04.002_bib0022","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3390\/v16091422","article-title":"Comparison of different HIV-1 resistance interpretation tools for next-generation sequencing in Italy","volume":"16","author":"Armenia","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.jgar.2025.04.002_bib0023","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"Journal of the Royal Statistical Society: Series B (Methodological)"},{"key":"10.1016\/j.jgar.2025.04.002_bib0024","doi-asserted-by":"crossref","DOI":"10.3390\/v12080838","article-title":"Genetic features of HIV-1 integrase sub-subtype A6 predominant in Russia and predicted susceptibility to INSTIs","volume":"12","author":"Kirichenko","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.jgar.2025.04.002_bib0025","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/cid\/ciad370","article-title":"Expanded multivariable models to assist patient selection for long-acting cabotegravir + rilpivirine treatment: clinical utility of a combination of patient, drug concentration, and viral factors associated with virologic failure","volume":"77","author":"Orkin","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.04.002_bib0026","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01702-21","article-title":"Impact of integrase sequences from HIV-1 subtypes A6\/A1 on the In vitro potency of cabotegravir or rilpivirine","volume":"66","author":"Jeffrey","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.04.002_bib0027","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/infdis\/jiad291","article-title":"Effect of the L74I polymorphism on fitness of cabotegravir-resistant variants of human immunodeficiency virus 1 subtype A6","volume":"228","author":"Hu","year":"2023","journal-title":"J Infect Dis"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221371652500075X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221371652500075X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T12:18:01Z","timestamp":1750853881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221371652500075X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":27,"alternative-id":["S221371652500075X"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2025.04.002","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of low-frequency integrase strand transfer inhibitor resistance mutations on virological outcomes in antiretroviral therapy-na\u00efve individuals initiating second-generation integrase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2025.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}